Dragonfly, Bristol Myers Squibb to develop immunotherapies

By The Science Advisory Board staff writers

Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple sclerosis and neuroinflammatory targets.

Under the agreement, Bristol Myers Squibb will have the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary Trinket technology platform. Bristol Myers Squibb will pay Dragonfly a $55 million upfront payment, and Dragonfly will be eligible for additional development, regulatory, and milestone payments, as well as royalties on sales of approved product sales.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: